Freedom251 › AI Drug Discovery Software
CONVERGE
Facts from CONVERGE's own pages
- Commercial access
- Verge describes engagement models ranging from full target-discovery campaigns to focused human-relevance assessments. · vergelabs.com, 14 Nov 2026
- Company
- Verge Labs says it started as Verge Genomics in 2015 and became Verge Labs in 2026. · vergelabs.com, 14 Nov 2026
- Data collection
- VergeDB is built from brain tissue partnerships and includes transcriptomic, genetic, clinical, and multi-omics data. · vergelabs.com, 14 Nov 2026
- Founded
- 2015 · vergelabs.com, 21 Oct 2026
- Headquarters
- San Francisco, California · vergelabs.com, 21 Oct 2026
- Model
- Its model infers an individual patient's brain molecular state from a routine blood draw and predicts drug response. · vergelabs.com, 14 Nov 2026
- Product
- CONVERGE is an AI operating system for neuroscience drug development combining foundation models and systems-biology workflows. · vergelabs.com, 14 Nov 2026
- Program enablement
- CONVERGE helps teams evaluate target pathways, patient subgroups, preclinical models, and indication opportunities. · vergelabs.com, 14 Nov 2026
- Scale
- The company's platform data page reports 12,000 brain transcriptomes, 6,000+ neurological patients and controls, and 15M single-cell profiles. · vergelabs.com, 14 Nov 2026
- Security and integrations
- The opened official product pages do not state security certifications or third-party integrations. · vergelabs.com, 14 Nov 2026
- Support
- Verge says it aims to reply to platform and partnership inquiries within two business days. · vergelabs.com, 14 Nov 2026
- Target discovery
- The platform identifies disease signatures and targets using multimodal patient data and human tissue and genetics. · vergelabs.com, 14 Nov 2026
- Training data
- The foundation model is trained on proprietary multimodal CNS patient data and can be tuned with program- and trial-specific data. · vergelabs.com, 14 Nov 2026
- Trial optimization
- It stratifies trial populations by molecular endotype and identifies likely-benefit subgroups and pharmacodynamic biomarkers. · vergelabs.com, 14 Nov 2026
- Users
- The product is presented for drug developers working on neuroscience and CNS programs. · vergelabs.com, 14 Nov 2026
Where CONVERGE stands on Freedom251
- AI Drug Discovery Software#12 of 33